Personalising Diabetes Care in Europe and Beyond: MELISSA Project Launches Clinical Trial

Our diabetes project MELISSA has officially launched a clinical trial to test its platform, marking a major milestone on the path toward personalised, AI-driven diabetes management.

For the first time, the team brings together two AI engines in one platform: automated, real-time dietary assessment and self-learning advisor for insulin dosing, enabling fully personalised therapy. Following extensive in-silico testing and a successful feasibility study earlier this year, the MELISSA platform is now ready for practical testing.

The multicentre clinical trial will take place across Denmark, Germany, Greece, and the Netherlands, involving around 500 people with type 1 and type 2 diabetes on multiple daily insulin injections over a period of 22 weeks. Both individuals with diabetes and healthcare professionals will test the MELISSA platform to refine and validate its real-world applications. The platform underpins a web service for healthcare providers and a smartphone app for people living with diabetes.

Transforming Personalised Insulin Therapy

The MELISSA app is designed to offer people with diabetes personalised insulin intake guidance, enabling them to make more knowledgeable treatment decisions, significantly enhancing their overall quality of life. This innovative way of personalising insulin use relies on a comprehensive self-learning system – ABBA algorithm – that continuously learns and adapts to optimise daily insulin dosing based on individual needs, independent of the diabetes management technology in use.

The mobile app integrated into the platform combines real-time dietary assessment and optimised insulin dosing, while personalising recommendations based on individual eating habits. Additionally, the platform can work with any type of glucose monitoring device, making it accessible to a wide range of users and healthcare providers. Extensive in-silico validation – which means using computer simulations for tests – has ensured the platform’s accuracy and effectiveness in personalising insulin therapy for each user.

By integrating two AI engines in a single platform, MELISSA aims to make expert-level insulin recommendations accessible to everyone. The mobile app offers personalised insulin dosing advice and adapts continuously to each user’s habits and glucose data — independent of the technology they use.

“MELISSA will offer individuals with diabetes and healthcare providers a tool for effective, data-driven diabetes management,” says project coordinator Bastiaan de Galan.

With this clinical trial, MELISSA takes an important step towards improving diabetes care in Europe and beyond through validated, user-centred AI solutions.

Learn more about the clinical study on the MELISSA website